A phase II study of intensified chemotherapy alone as initial treatment for newly diagnosed anaplastic oligodendroglioma: An interim analysis

Journal of Neuro-Oncology

Volumn 89, Issue 2, 2008, Pages 187-193

  Mohile, Nimish A ^a   Forsyth, Peter ^b   Stewart, Douglas ^b   Raizer, Jeffrey J ^c   Paleologos, Nina ^d   Kewalramani, Tarun ^a   Louis, David N ^e   Cairncross, J Gregory ^b   Abrey, Lauren E ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF CALGARY   (Canada)

^c NORTHWESTERN UNIVERSITY   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

19q; 1p; Anaplastic oligodendroglioma; Chemotherapy; Procarbazine

Indexed keywords

ANTINEOPLASTIC AGENT; BUSULFAN; COLONY STIMULATING FACTOR; GRANULOCYTE COLONY STIMULATING FACTOR; INFUSION FLUID; LOMUSTINE; PROCARBAZINE; THIOTEPA; VINCRISTINE;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADULT; ANAPLASTIC OLIGOASTROCYTOMA; ANAPLASTIC OLIGODENDROGLIOMA; ARTICLE; ASCITES; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BRAIN CANCER; BRAIN DISEASE; CHROMOSOME 19Q; CHROMOSOME 1P; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; DEATH; DEHYDRATION; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG RESPONSE; DRUG WITHDRAWAL; EPILEPSY; FATIGUE; FEBRILE NEUTROPENIA; GENE DELETION; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; HYPOTENSION; INFECTION; LIVER DYSFUNCTION; LIVER VENOOCCLUSIVE DISEASE; LUNG TOXICITY; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; MYELOABLATIVE CONDITIONING; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PANCREATITIS; PHASE 2 CLINICAL TRIAL; PROGNOSIS; THROMBOCYTOPENIA; VEIN OCCLUSION; VOMITING;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASTROCYTOMA; BRAIN NEOPLASMS; BUSULFAN; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; KARNOFSKY PERFORMANCE STATUS; LOMUSTINE; MALE; MIDDLE AGED; OLIGODENDROGLIOMA; PROCARBAZINE; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; THIOTEPA; VINCRISTINE;

EID: 48749095614     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-008-9603-8     Document Type: Article

References (15)

1. Cairncross G, Macdonald D, Ludwin S et al (1994) Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 12:2013-2021
2. Cairncross G, Berkey B, Shaw E et al (2006) Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 24:2707-2714
3. van den Bent MJ, Carpentier AF, Brandes AA et al (2006) Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: A randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 24:2715-2722
4. Crossen JR, Garwood D, Glatstein E, Neuwelt EA (1994) Neurobehavioral sequelae of cranial irradiation in adults: A review of radiation-induced encephalopathy. J Clin Oncol 12:627-642
5. Paleologos NA, Macdonald DR, Vick NA, Cairncross JG (1999) Neoadjuvant procarbazine, CCNU, and vincristine for anaplastic and aggressive oligodendroglioma. Neurology 53:1141-1143
6. Abrey LE, Childs BH, Paleologos N et al (2003) High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma. J Neurooncol 65:127-134
7. Abrey LE, Childs BH, Paleologos N et al (2006) High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: Long-term follow-up. Neuro Oncol 8:183-188
8. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) (2007) World Health Organization International Agency for Research on Cancer.
9. Macdonald DR, Cascino TL, Schold SC, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277-1280
10. Stupp R, Mason WP, Van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987-996
11. Abrey LE, Louis DN, Paleologos N et al (2007) Survey of treatment recommendations for anaplastic oligodendroglioma. Neuro-Oncol 9:314-318
12. Careras E, Bertz H, Arcese W et al (1998) Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: A prospective cohort study of the European Group for Blood and Marrow Transplantation. Blood 92(10):3599-3604
13. Ridola V, Grill J, Doz F et al (2007) High-dose chemotherapy with autologous stem cell rescue followed by posterior fossa irradiation for local medulloblastoma recurrence of progression after conventional chemotherapy. Cancer 110:156-163
14. Jenkins RB, Blair H, Ballman KV et al (2006) a t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 66(20):9852-9861
15. Ino Y, Betensky RA, Zlatescu MC et al (2001) Molecular subtypes of anaplastic oligodendroglioma: Implications for patient management at diagnosis. Clin Cancer Res 7:839-845